April 2, 2018 / 11:09 AM / 21 days ago

BRIEF-Synlogic Doses First Patient In Phase 1b/2a Trial Of SYNB1020 For Treatment Of Hyperammonemia In Patients With Cirrhosis

April 2 (Reuters) - Synlogic Inc:

* SYNLOGIC DOSES FIRST PATIENT IN PHASE 1B/2A TRIAL OF SYNB1020 FOR TREATMENT OF HYPERAMMONEMIA IN PATIENTS WITH CIRRHOSIS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below